MAVENIR
30.9.2021 15:02:04 CEST | Business Wire | Press release
Mavenir, the Network Software Provider building the future of networks with cloud-native software that runs on any cloud and transforms the way the world connects, today announced its next-generation Operations Support System (ngOSS) , a new addition to the MAVscale platform.
The new solution brings together a powerful combination of Artificial Intelligence (AI), Analytics, Automation, and Orchestration, backed by Mavenir’s experience delivering telecom network solutions to allow Communication Service Providers (CSPs) to deploy ngOSS in their 4G networks today, while at the same time preparing to fully realize the potential of 5G capabilities through intelligent network operations.
By enhancing network performance, Mavenir’s ngOSS enables CSPs to improve the overall customer experience, lower operating expenses (OPEX), and reduce the risk of manual errors more prevalent in legacy OSS systems.
The end-to-end, cloud-native automation framework is built based on TM Forum’s Open Digital Architecture (ODA) and OpenAPIs that uses enhanced AI and Machine Learning (ML) models to deliver advanced network performance. Engineered with a microservices-based architecture, Mavenir's ngOSS solution simplifies large, legacy, monolithic systems into smaller, autonomous components that offer intelligence, insights, and network control. A more open, automated network is necessary to break legacy vendor lock-in while driving innovation for 5G use cases.
Mavenir is an OSS vendor with 4G/5G and mobile core/Radio Access Network (RAN) expertise, and in-depth understanding of orchestrating telecommunications workloads required for enabling advanced 5G capabilities, including network slicing, which translates directly into efficiencies for the CSPs.
“As CSPs advance toward automation, next-generation OSS will be a critical component to enable the network of the future,” said Kuntal Chowdhury, SVP and GM of AI and Analytics at Mavenir. “Using advanced AI and ML models to enhance network performance will help CSPs deliver superior customer experience, while scalable automation reduces manual tasks to lower maintenance costs and reduces the risk of human error. Mavenir’s ngOSS solution allows CSPs to break open the network and take advantage of Open APIs to increase agility and innovation, introduce new services, and monetize 5G with rapid service velocity.”
Key capabilities of Mavenir’s ngOSS include:
- Service Fulfillment and Orchestration – Service Order Management integrates with the Business Support System (BSS) layer using Open APIs to deliver dynamic order creation, support complex workflow creation, and offer complete visibility & management into service order execution. Service Orchestration provides a complete network automation solution, including Service Design, 5G Slice Management, and Network Service Orchestration.
- Data Management – Mavenir’s Provisioning and Activation function is radically different from the traditional provisioning offerings from legacy vendors. It elevates provisioning to a whole new level by offering Provisioning-as-a-Service on any cloud, from any vendor, on any domain approach. In addition, Mavenir’s Active Inventory collects, maintains, and exposes a federated real-time view of available network resources and services from across multiple cloud and vendor environments.
- Service Assurance and AI Operations (AIOps) – Mavenir Service Assurance and AIOps platform addresses CSP’s operational challenges by providing end-to-end visibility into the network, enabling an open network by integrating with any cloud, any vendor, and any technology domain, and performing critical AIOps functions, such as AI-driven predictive alarm correlation, ML-assisted Ticket Analysis, and auto Root Cause Analysis (RCA), resulting in increased productivity, shorter Mean Time To Repair (MTTR), and OPEX savings.
- Domain Controllers – Mavenir’s Non-Real-Time RAN Intelligent Controller (RIC) is a containerized application that uses advanced machine learning algorithms to optimize RAN performance and train ML models using long term RAN data for dynamic and adaptive policy and control. Mavenir’s Network Subnet Slice Management Function (NSSMF) is an open, cloud-native, and vendor-agnostic function that plays a crucial role in 5G slice management as it does the last-mile connections necessary to configure a slice.
Supporting documents:
Mavenir ngOSS webpage
Mavenir ngOSS solution brief
About Mavenir
Mavenir is building the future of networks and pioneering advanced technology, focusing on the vision of a single, software-based automated network that runs on any cloud. As the industry’s only end-to-end, cloud-native network software provider, Mavenir is focused on transforming the way the world connects, accelerating software network transformation for 250+ Communications Service Providers in over 120 countries, which serve more than 50% of the world’s subscribers. www.mavenir.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210930005144/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Fujirebio Expands Access in Canada to Blood-based Neurology Testing with Health Canada Class II Medical Device Licenses for the Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma Assays1.9.2026 07:00:00 CEST | Press release
H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Health Canada has issued Class II Medical Device Licenses (MDL) for the Lumipulse G NfL Blood and the Lumipulse G pTau 217 Plasma assay for use on the fully automated LUMIPULSE® G immunoassay platform in the Canadian market. "The approval of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for clinical use in Canada marks another important step in our mission to expand access to reliable and clinically meaningful blood-based biomarkers for clinicians and patients worldwide," said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “As a pioneer in neurological diagnostics, Fujirebio remains committed to advancing patient care through innovative, fully automated testing solutions." These approvals further strengthen Fujirebio’s comprehensive neurological diagnostics portfolio by broadening access to high-quality biomarker solutions designed to inform clinical decision-making across the
Helical Fusion Named a Final Candidate for Japan’s METI Fusion Power Demonstration Program1.9.2026 04:00:00 CEST | Press release
Milestone-based government program supports multiple fusion approaches toward power demonstration and commercialization Helical Fusion Co., Ltd., a fusion energy company developing a Helical Stellarator toward commercially viable fusion power, has been named a final candidate for Japan’s Ministry of Economy, Trade and Industry (METI) program supporting the demonstration of fusion power generation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831991676/en/ Image of Helix HARUKA, Helical Fusion’s Integrated Demo Device(left), and Helix KANATA, Helical Fusion’s Fusion Pilot Plant(right) The program is designed to accelerate fusion power demonstration in the 2030s under Japan’s national energy and fusion strategies. It supports private-sector technology development across multiple fusion approaches, including tokamak, stellarator and laser fusion, with approximately JPY 60 billion in total government support anticipated ove
Strategic Combination of ITC Infotech and Happiest Minds Technologies to Create a Scaled, Future-Ready, AI-First Global Technology Services Enterprise with US$ 1 Billion Revenue by FY28[1]31.8.2026 23:35:00 CEST | Press release
ITC Infotech Board approves proposed acquisition of 22.1% promoter stake and a Scheme of Amalgamation of the two companies ITC Infotech (ITCI), a wholly owned subsidiary of ITC Limited and a leading global technology services player, today announced the proposed strategic combination with Happiest Minds Technologies Limited (Happiest Minds) to create a scaled, future-ready, AI-first global technology services enterprise. The ITCI Board approved a proposal to acquire 22.1% equity stake from the promoter of Happiest Minds in two tranches under a Share Purchase Agreement. The transaction would be funded through a Rights Issue by ITC Infotech. ITCI Board has also approved a proposed Scheme of Amalgamation of Happiest Minds with ITCI which will be effected after the share acquisition. Pursuant to the scheme, the shares of ITCI will be listed on the stock exchanges. The proposed transaction has also been endorsed by the Board of Directors of ITC Limited. This strategic combination will syner
Angel’s Profits Grew Robustly in the First Half of 2026 with Europe and North America Turning Profitable Ahead of Schedule31.8.2026 21:07:00 CEST | Press release
Angelalign Technology Inc. (“Angel” or the “Company”) (6699.HK) (angelaligner.com), the second largest clear aligner supplier by revenue, announced today that its revenue grew 42.9% to US$230.7 million and net profit grew 79.6% to $25.5 million for the six months ending June 30, 2026. Angel’s business in Europe and North America crossed into profitability ahead of plan while the business in Chinese mainland delivered market share gains well above expectations. Doctors and staff in every region report that they are increasingly selecting Angel’s solutions after experiencing more predictable outcomes, especially on complex cases, and embracing the positive culture of the company. Dr. Mark Holt D.D.S., M.S. of Holt Orthodontics in Northern California, states: “We treat over half of our patients with clear aligners and our experience with Angel’s treatment plans and clear aligners has been tremendous.” “Our main focus is to provide great service to and being a rock-solid partner for our cu
BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines31.8.2026 21:00:00 CEST | Press release
Agreement advances patient access and strengthens BeOne's long-term commitment to U.S. innovation and manufacturing BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne's longstanding commitment to patient access and investment in research and scientific innovation. John V. Oyler, Co-Founder, Chairman and CEO, BeOne Medicines, said: “At BeOne, we believe every patient should benefit from innovative cancer therapies. We appreciate the Trump Administration’s commitment to advancing solutions that broaden access and scientific progress for American patients. This agreement reflects our purpose to reach more patients as we expand our U.S. investment in additional res
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
